



MEDESIS PHARMA SIGNS A PARTNERSHIP WITH PARTNER INTERNATIONAL, WORLD LEADER IN TRANSACTIONS BETWEEN BIOTECHS AND PHARMACEUTICAL LABORATORIES

Montpellier, April 4, 2023 at 8:00 a.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the administration of active ingredients in nano micelles by the buccal route, Aonys®, today announces the signature a partnership agreement with the North American Company PARTNER INTERNATIONAL, an international leader in transactions in the life sciences industry with more than three billion dollars in transactions concluded.

PARTNER INTERNATIONAL provides services to companies in the pharmaceutical and biotechnology industries who wish to expand their markets internationally. Partner International's list of services includes strategic partnerships, licensing, market research and valuations, mergers/acquisitions, and divestitures.

The PARTNER INTERNATIONAL team has many years of experience in business and business development and can quickly identify potential licensing opportunities internationally. With more than 45,000 companies in their network, they have strong relationships with CEOs and senior executives of leading companies around the world, thanks to their long history of transactions at all stages of development.

As part of the agreement with MEDESIS PHARMA scheduled for an initial period of 6 months renewable, PARTNER INTERNATIONAL will target key pharmaceutical companies with activity in the fields concerned by the preclinical and clinical developments of MEDESIS PHARMA, including all potential applications of the drug delivery platform, in particular the formulation of interfering RNAs to inhibit the expression of abnormal or overexpressed genes in neurodegenerative diseases including Huntington's disease, as well as in oncology for the treatment of aggressive cancers, and for the product NanoLithium under clinical study for the treatment of Alzheimer's disease. MEDESIS PHARMA thus intends to be able to accelerate the completion of some of its research programs and generate new sources of funding.

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood–brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 71 patents, the result of 17 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR0018444464 - ALMDP

For more information:

www.medesispharma.com

MEDESIS PHARMA

Jean Claude Maurel
Tel: +33 4 67 03 03 96
contact@medesispharma.com

CALYPTUS

Marie Calleux
Tel : +33 1 53 65 68 66
medesispharma@calyptus.net